ALK-positive large B-cell lymphoma

disease

On this page

Also known as ALK+ large B-cell lymphomaALK+ LBCLALK-DLBCLdiffuse large B-cell lymphoma with expression of full-length ALKdiffuse large B-cell lymphoma with expression of full-length anaplastic lymphoma kinase

Summary

ALK-positive large B-cell lymphoma (MONDO:0018225) is a cancer and 4 clinical trials. Top therapeutic interventions include glofitamab, nivolumab, and polatuzumab vedotin. A subtype of diffuse large B-cell lymphoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

Classification: Cancer
Clinical trials: 4

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	ALK-positive large B-cell lymphoma
Mondo ID	MONDO:0018225
Orphanet	364043
ICD-11	2077559619
NCIT	C7225
SNOMED CT	715950008
UMLS	C1333294
MedGen	232429
GARD	0021564
Is cancer (heuristic)	yes

Also known as: ALK+ large B-cell lymphoma · ALK+ LBCL · ALK-DLBCL · ALK-positive large B-cell lymphoma · diffuse large B-cell lymphoma with expression of full-length ALK · diffuse large B-cell lymphoma with expression of full-length anaplastic lymphoma kinase

Disease family

This is a subtype of diffuse large B-cell lymphoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › immune system disorder › leukocyte disorder › B-cell neoplasm › neoplasm of mature B-cells › diffuse large B-cell lymphoma › ALK-positive large B-cell lymphoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 4.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	2
PHASE1	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03038672	PHASE2	ACTIVE_NOT_RECRUITING	Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas
NCT06834373	PHASE2	RECRUITING	Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy
NCT04231877	PHASE1	RECRUITING	Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma
NCT05544019	PHASE1	RECRUITING	Study of SGR-1505 in Mature B-Cell Neoplasms

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
GLOFITAMAB	4	1
NIVOLUMAB	4	1
POLATUZUMAB VEDOTIN	4	1
GOLCADOMIDE	3	1
VARLILUMAB	2	1
SGR-1505	1	1

Drugs: Glofitamab, Nivolumab, Polatuzumab Vedotin, Golcadomide